Nothing Special   »   [go: up one dir, main page]

MX2021006734A - Metodo para tratar el cancer. - Google Patents

Metodo para tratar el cancer.

Info

Publication number
MX2021006734A
MX2021006734A MX2021006734A MX2021006734A MX2021006734A MX 2021006734 A MX2021006734 A MX 2021006734A MX 2021006734 A MX2021006734 A MX 2021006734A MX 2021006734 A MX2021006734 A MX 2021006734A MX 2021006734 A MX2021006734 A MX 2021006734A
Authority
MX
Mexico
Prior art keywords
treating cancer
inhibitor
ezh2
methods
pharmaceutical compositions
Prior art date
Application number
MX2021006734A
Other languages
English (en)
Inventor
Heike Keilhack
Brett Truitt
Yuta Suzuki
Tsukasa Murase
Futoshi Shikata
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MX2021006734A publication Critical patent/MX2021006734A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden inhibidor(es) de la histona metiltransferasa EZH2 humana, y a método de terapia contra el cáncer que usan el/los inhibidor(es) de EZH2.
MX2021006734A 2014-11-17 2017-05-09 Metodo para tratar el cancer. MX2021006734A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US201562251903P 2015-11-06 2015-11-06

Publications (1)

Publication Number Publication Date
MX2021006734A true MX2021006734A (es) 2021-07-02

Family

ID=56014476

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006089A MX2017006089A (es) 2014-11-17 2015-11-17 Metodo para tratar el cancer.
MX2021006734A MX2021006734A (es) 2014-11-17 2017-05-09 Metodo para tratar el cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017006089A MX2017006089A (es) 2014-11-17 2015-11-17 Metodo para tratar el cancer.

Country Status (21)

Country Link
US (2) US10786511B2 (es)
EP (2) EP3220916B1 (es)
JP (3) JP6829684B2 (es)
KR (3) KR102644844B1 (es)
CN (2) CN107249591B (es)
AU (3) AU2015350108B2 (es)
BR (1) BR112017010166A2 (es)
CA (1) CA2967664A1 (es)
DK (1) DK3220916T3 (es)
EA (1) EA201791095A1 (es)
ES (1) ES2947819T3 (es)
FI (1) FI3220916T3 (es)
HU (1) HUE062159T2 (es)
IL (3) IL296080B2 (es)
LT (1) LT3220916T (es)
MX (2) MX2017006089A (es)
PL (1) PL3220916T3 (es)
PT (1) PT3220916T (es)
SG (1) SG11201703806XA (es)
SI (1) SI3220916T1 (es)
WO (1) WO2016081523A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160303135A1 (en) 2013-12-06 2016-10-20 Epizyme, Inc. Combination therapy for treating cancer
SG10201811128RA (en) 2014-06-17 2019-01-30 Epizyme Inc Ezh2 inhibitors for treating lymphoma
CN107249591B (zh) 2014-11-17 2024-01-30 Epizyme股份有限公司 固体药物配制品及其制备方法
SG10201902664RA (en) 2015-04-20 2019-04-29 Epizyme Inc Combination therapy for treating cancer
AU2016275051A1 (en) 2015-06-10 2017-12-07 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
JP2018525414A (ja) 2015-08-24 2018-09-06 エピザイム，インコーポレイティド 癌を処置するための方法
WO2017132518A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
EP3464643A4 (en) 2016-06-01 2020-04-01 Epizyme Inc USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
TW201831181A (zh) 2017-01-19 2018-09-01 日商第一三共股份有限公司 用以用於治療ｈｔｌｖ－１相關脊髓病之醫藥組成物
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
CN110944628A (zh) 2017-06-02 2020-03-31 Epizyme股份有限公司 使用ezh2抑制剂治疗癌症
JP7399079B2 (ja) 2017-09-05 2023-12-15 エピザイム，インコーポレイティド 癌を処置するための併用療法
IL294108A (en) * 2019-12-20 2022-08-01 Epizyme Inc Crystalline salt of hydrobromide of ezh2 inhibitor, its preparation and effective pharmaceutical composition for cancer treatment
JP2022167451A (ja) 2021-04-23 2022-11-04 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
AU2023262308A1 (en) 2022-04-27 2024-10-03 Astrazeneca Uk Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
CA3176977A1 (en) 2010-09-10 2012-03-15 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP2663283B1 (en) * 2011-01-14 2017-05-10 Bristol-Myers Squibb Company High drug load tablet formulation of brivanib alaninate
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CA2867282C (en) * 2012-03-12 2024-04-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
SI3184523T1 (sl) 2012-04-13 2020-04-30 Epizyme Inc N-((4,6 dimetil-2-okso-L,2-dihidropiridin-3-IL)metil)-5-(etil (tetrahidro-2H-piran-4-IL)amino)-4-metil-4'-(morfolinometil)-(L, 1'- bifen IL)-3-karboksamid hidrobromid za uporabo pri zdravljenju celične proliferativne motnje hematološkega sistema
IL308807A (en) * 2012-04-13 2024-01-01 Epizyme Inc Combined treatment for cancer
EP3725314A1 (en) 2012-10-15 2020-10-21 Epizyme, Inc. Substituted benzene compounds
MX2015004771A (es) * 2012-10-15 2016-01-08 Epizyme Inc Metodos para tratar cancer.
WO2014100080A1 (en) * 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
EP2935264B1 (en) 2012-12-21 2017-10-18 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
WO2014100646A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
EP2970281A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BENZENE COMPOUNDS
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
HUE063984T2 (hu) * 2013-10-16 2024-02-28 Epizyme Inc Hidroklorid só forma az EZH2 gátlásához
EP3057594A4 (en) * 2013-10-18 2017-06-07 Epizyme, Inc. Method of treating cancer
US20160303135A1 (en) 2013-12-06 2016-10-20 Epizyme, Inc. Combination therapy for treating cancer
SG10201811128RA (en) * 2014-06-17 2019-01-30 Epizyme Inc Ezh2 inhibitors for treating lymphoma
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
WO2016061507A1 (en) 2014-10-16 2016-04-21 Epizyme, Inc. Method for treating cancer
CN107249591B (zh) 2014-11-17 2024-01-30 Epizyme股份有限公司 固体药物配制品及其制备方法
AU2016275051A1 (en) * 2015-06-10 2017-12-07 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
US11147819B2 (en) * 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer

Also Published As

Publication number Publication date
AU2024201171A1 (en) 2024-03-14
AU2021204706A1 (en) 2021-07-29
KR102338802B1 (ko) 2021-12-14
JP7485810B2 (ja) 2024-05-16
US10786511B2 (en) 2020-09-29
US20170360797A1 (en) 2017-12-21
CA2967664A1 (en) 2016-05-26
KR20170103768A (ko) 2017-09-13
IL296080B1 (en) 2023-08-01
US20210060030A1 (en) 2021-03-04
PT3220916T (pt) 2023-06-26
SI3220916T1 (sl) 2023-09-29
PL3220916T3 (pl) 2023-08-14
IL296080A (en) 2022-11-01
KR20210156840A (ko) 2021-12-27
IL304252A (en) 2023-09-01
NZ768247A (en) 2024-05-31
KR102644844B1 (ko) 2024-03-07
LT3220916T (lt) 2023-07-25
EA201791095A1 (ru) 2017-10-31
AU2021204706B2 (en) 2023-11-23
KR20240035908A (ko) 2024-03-18
CN116650500A (zh) 2023-08-29
CN107249591B (zh) 2024-01-30
JP2023062189A (ja) 2023-05-02
DK3220916T3 (da) 2023-06-26
MX2017006089A (es) 2017-12-11
IL252182A0 (en) 2017-07-31
IL252182B2 (en) 2023-02-01
EP3220916B1 (en) 2023-04-19
IL296080B2 (en) 2023-12-01
JP2021073241A (ja) 2021-05-13
EP3220916A1 (en) 2017-09-27
JP6829684B2 (ja) 2021-02-10
JP2017537899A (ja) 2017-12-21
AU2015350108A1 (en) 2017-05-25
NZ731696A (en) 2024-03-22
HUE062159T2 (hu) 2023-10-28
AU2015350108B2 (en) 2021-04-08
IL252182B (en) 2022-10-01
ES2947819T3 (es) 2023-08-21
EP4272742A1 (en) 2023-11-08
EP3220916A4 (en) 2018-07-11
CN107249591A (zh) 2017-10-13
BR112017010166A2 (pt) 2018-02-14
WO2016081523A1 (en) 2016-05-26
FI3220916T3 (fi) 2023-06-19
SG11201703806XA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
MX2021006734A (es) Metodo para tratar el cancer.
MX2018002344A (es) Metodo para tratar el cancer.
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
EP3368559A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2016007351A (es) Terapia de combinacion para tratar cancer.
GB2541571A (en) Pharmaceutical compositions
IL253979B (en) Methods, preparations and kits for cancer treatment
EP3320093A4 (en) COMPOSITIONS AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION AND TREATMENT OF CANCER USING SLNCR ISOFORMS
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
EP3464643A4 (en) USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
EP3353204A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL254842A0 (en) Therapeutic preparations and methods for use in cancer treatment
PH12018502154A1 (en) Methods of treating ocular conditions
IL268163A (en) Methods, compositions, and kits for treatment of cancer
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EP3113775A4 (en) Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
ZA201703467B (en) Methods of treating ocular conditions
EP3630080A4 (en) USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
MX2017003463A (es) Inhibidores de histona desmetilasa.